Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on December 10, 2020. The registrant is a Delaware corporation with its principal executive offices in High Point, NC, and its Class A common stock trades on the NASDAQ Capital Market under the symbol VTVT. The company is designated as an emerging growth company.
Key Financial Metrics
This filing reports a specific capital transaction rather than periodic financial performance metrics (e.g., revenue, profit, or cash flow).
- Capital Raised: $1.0 million.
- Shares Issued: 625,000 shares of Class A common stock.
- Price Per Share: $1.60.
- Investor: MacAndrews & Forbes Group LLC.
The filing text does not provide clear values for revenue, operating margins, total debt, or liquidity positions as this is not a periodic financial report.
Material Changes
The primary material change reported is the execution of a capital raise pursuant to a letter agreement dated December 23, 2019. The Company exercised its right to require the Investor to purchase the shares, resulting in an immediate infusion of $1.0 million in cash.
Management Commentary, Risks, and Unusual Items
Executive Employment Agreements: On December 10, 2020, the Company entered into new employment agreements with its top executives, replacing prior agreements with substantially similar terms:
- Stephen L. Holcombe: President and Chief Executive Officer. The agreement extends his tenure through December 31, 2021.
- Rudy C. Howard: Executive Vice President and Chief Financial Officer. The agreement extends his tenure through December 31, 2021.
Unusual Items: The capital raise was triggered by the Company exercising a specific right under the December 2019 Letter Agreement to force the purchase of shares by the Investor.
Investor Verification Checklist
- Verify the terms of the December 2019 Letter Agreement (Exhibit 10.25 to the 2020 Form 10-K) to understand the conditions under which the Company can compel the Investor to purchase shares.
- Review the full text of the new Employment Agreements (Exhibits 10.1 and 10.2) to confirm compensation details and termination provisions for the CEO and CFO.
- Confirm the current cash position and burn rate in the most recent Form 10-Q or 10-K to assess the impact of the $1.0 million infusion on the company's runway.
- Check for any subsequent filings regarding the utilization of the raised capital.